{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:25:30Z","timestamp":1787109930727,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["M0366"],"award-info":[{"award-number":["M0366"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital","doi-asserted-by":"publisher","award":["202205"],"award-info":[{"award-number":["202205"]}],"id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012131","name":"Department of Science and Technology of Liaoning Province","doi-asserted-by":"publisher","award":["2022-BS\\u2212121"],"award-info":[{"award-number":["2022-BS\\u2212121"]}],"id":[{"id":"10.13039\/501100012131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2024-MSLH\\u2212562"],"award-info":[{"award-number":["2024-MSLH\\u2212562"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072835"],"award-info":[{"award-number":["82072835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105395","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:34:58Z","timestamp":1779899698000},"page":"105395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular understanding and clinical aspects of adoptive cellular immunotherapy in prostate cancer"],"prefix":"10.1016","volume":"225","author":[{"given":"Xinhong","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-9182","authenticated-orcid":false,"given":"Kefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105395_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105395_bib2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","article-title":"Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer","volume":"69","author":"Ananias","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2026.105395_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1535-7163.MCT-20-0061","article-title":"TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors","volume":"20","author":"Austin","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105395_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105395_bib7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105395_bib8","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-20-3770","article-title":"Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib9","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105395_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0960-9822(00)00568-6","article-title":"Adhesion to target cells is disrupted by the killer cell inhibitory receptor","volume":"10","author":"Burshtyn","year":"2000","journal-title":"Curr. Biol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib13","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105395_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.178.2.647","article-title":"Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation","volume":"178","author":"Carr","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib15","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib16","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105395_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105395_bib18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105395_bib19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105395_bib20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105395_bib21","article-title":"A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells","volume":"7","author":"De Bruin","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105395_bib22","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib23","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/eji.200838434","article-title":"Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function","volume":"38","author":"Chiesa","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib24","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I\/II Study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105395_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00109-008-0417-0","article-title":"Permanent silencing of NKG2A expression for cell-based therapeutics","volume":"87","author":"Figueiredo","year":"2009","journal-title":"J. Mol. Med. (Berl. )"},{"key":"10.1016\/j.critrevonc.2026.105395_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in Cancer - Beyond Immune Regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105395_bib29","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","article-title":"Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens","volume":"11","author":"Friedrich","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105395_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nbt.4090","article-title":"Driving T-cell immunotherapy to solid tumors","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-030-17864-2_3","article-title":"HLA Class-I Expression and Cancer Immunotherapy","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2026.105395_bib33","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1615\/CritRevImmunol.v18.i5.10","article-title":"CD28\/B7 costimulation: a review","volume":"18","author":"Greenfield","year":"1998","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2159-8290.CD-24-1213","article-title":"Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer","volume":"16","author":"Gumpert","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105395_bib37","doi-asserted-by":"crossref","first-page":"84359","DOI":"10.18632\/oncotarget.12711","article-title":"Inducible expression of cancer-testis antigens in human prostate cancer","volume":"7","author":"Heninger","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105395_bib38","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105395_bib39","doi-asserted-by":"crossref","first-page":"15877","DOI":"10.1073\/pnas.1209042109","article-title":"T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells","volume":"109","author":"Hillerdal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105395_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade4186","article-title":"PD-L1 methylation restricts PD-L1\/PD-1 interactions to control cancer immune surveillance","volume":"9","author":"Huang","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105395_bib42","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib43","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","article-title":"STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors","volume":"96","author":"Hubert","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105395_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE(\u00ae) immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2026.105395_bib45","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105395_bib46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105395_bib47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","article-title":"Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer","volume":"26","author":"Jin","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2026.105395_bib48","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105395_bib50","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-024-03817-z","article-title":"Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells","volume":"74","author":"Khaliulin","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105395_bib52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41391-021-00319-2","article-title":"Clinical significance of STEAP1 extracellular vesicles in prostate cancer","volume":"24","author":"Khanna","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105395_bib53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib54","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105395_bib55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib56","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrurol.2012.117","article-title":"Cancer\/testis antigens and urological malignancies","volume":"9","author":"Kulkarni","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib57","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105395_bib58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nature10117","article-title":"SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx","volume":"474","author":"Laguette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105395_bib59","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib60","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105395_bib61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib62","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.critrevonc.2026.105395_bib64","article-title":"Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments","author":"Li","year":"2023","journal-title":"Chin. Med. J. (Engl. )."},{"key":"10.1016\/j.critrevonc.2026.105395_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell. Stem Cell."},{"key":"10.1016\/j.critrevonc.2026.105395_bib66","article-title":"HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer","author":"Likasitwatanakul","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105395_bib67","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in Black men with prostate cancer: A literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105395_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib69","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib70","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib71","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib72","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.22749","article-title":"Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy","volume":"74","author":"Ma","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2026.105395_bib73","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematother. Stem Cell. Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2026.105395_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814347","article-title":"Emerging Immunotherapy Approaches for Treating Prostate Cancer","volume":"24","author":"Meng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105395_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061382","article-title":"Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer","volume":"9","author":"Montagner","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105395_bib77","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib78","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105395_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1285661","article-title":"Targeting STEAP1 as an anticancer strategy","volume":"13","author":"Nakamura","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib81","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib82","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0008-8749(86)90015-8","article-title":"Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes","volume":"100","author":"Nishimura","year":"1986","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib83","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.critrevonc.2026.105395_bib84","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","article-title":"A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab","volume":"25","author":"Nowicki","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060994","article-title":"Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy","volume":"11","author":"Paasch","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105395_bib86","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105395_bib87","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib88","doi-asserted-by":"crossref","first-page":"ra38","DOI":"10.1126\/scisignal.2000500","article-title":"TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1","volume":"3","author":"Peng","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2026.105395_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib90","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105395_bib92","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public. Health"},{"key":"10.1016\/j.critrevonc.2026.105395_bib93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib94","doi-asserted-by":"crossref","first-page":"C975","DOI":"10.1152\/ajpcell.00506.2004","article-title":"Is prostate-specific membrane antigen a multifunctional protein?","volume":"288","author":"Rajasekaran","year":"2005","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib95","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib96","article-title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial","volume":"15","author":"Rohaan","year":"2022","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib97","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"A Prelim. Report. N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib98","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105395_bib99","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105395_bib100","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105395_bib101","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105395_bib102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri2095","article-title":"TGFbeta signalling in control of T-cell-mediated self-reactivity","volume":"7","author":"Rubtsov","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib103","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell. Stem Cell."},{"key":"10.1016\/j.critrevonc.2026.105395_bib104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1479-5876-9-153","article-title":"Cancer\/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy","volume":"9","author":"Shiraishi","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib105","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105395_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105395_bib107","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib108","article-title":"Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib109","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105395_bib110","first-page":"80","article-title":"shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells. Vavilovskii Zhurnal Genet Selektsii","volume":"24","author":"Subrakova","year":"2020"},{"key":"10.1016\/j.critrevonc.2026.105395_bib111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tam","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105395_bib112","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105395_bib113","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib114","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/2326-6066.CIR-24-0119","article-title":"TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer","volume":"13","author":"Van Amerongen","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105395_bib115","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Van Der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105395_bib116","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-020-04221-0","article-title":"Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies","volume":"99","author":"Viardot","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105395_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105395_bib120","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2478\/jtim-2023-0122","article-title":"Circular RNA: A promising new star of vaccine","volume":"11","author":"Xie","year":"2023","journal-title":"J. Transl. Int. Med."},{"key":"10.1016\/j.critrevonc.2026.105395_bib121","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-025-01743-w","article-title":"PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib122","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105395_bib123","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib124","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105395_bib126","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105395_bib127","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105395_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109427","article-title":"PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models","volume":"9","author":"Zuccolotto","year":"2014","journal-title":"PLoS. One"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:38:17Z","timestamp":1787107097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":128,"alternative-id":["S1040842826002829"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105395","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular understanding and clinical aspects of adoptive cellular immunotherapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105395"}}